Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
http://dx.doi.org/10.25673/115168
Titel: | Economic evaluation of Motor Neuron Diseases : a nationwide cross-sectional analysis in Germany |
Autor(en): | Heinrich, Felix Cordts, Isabell ![]() Günther, René Stolte, Marcel Benjamin ![]() Zeller, Daniel ![]() Schröter, Carsten Weyen, Ute ![]() Regensburger, Martin ![]() Wolf, Joachim Schneider, Ilka ![]() Hermann, Andreas ![]() Metelmann, Moritz Kohl, Zacharias ![]() Linker, Ralf A. Koch, Jan Christoph ![]() Radelfahr, Florentine ![]() Schönfelder, Erik Gardt, Pavel Mohajer-Peseschkian, Tara Osmanovic, Alma ![]() Klopstock, Thomas Dorst, Johannes ![]() Ludolph, Albert C. ![]() Schöffski, Oliver Boentert, Matthias ![]() Hagenacker, Tim ![]() Deschauer, Marcus ![]() Lingor, Paul ![]() Petri, Susanne ![]() Schreiber-Katz, Olivia |
Erscheinungsdatum: | 2023 |
Art: | Artikel |
Sprache: | Englisch |
Zusammenfassung: | Background and objectives: Motor Neuron Diseases (MND) are rare diseases but have a high impact on affected individuals and society. This study aims to perform an economic evaluation of MND in Germany. Methods: Primary patient-reported data were collected including individual impairment, the use of medical and non-medical resources, and self-rated Health-Related Quality of Life (HRQoL). Annual socio-economic costs per year as well as Quality-Adjusted Life Years (QALYs) were calculated. Results: 404 patients with a diagnosis of Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) or Hereditary Spastic Paraplegia (HSP) were enrolled. Total annual costs per patient were estimated at 83,060€ in ALS, 206,856€ in SMA and 27,074€ in HSP. The main cost drivers were informal care (all MND) and disease-modifying treatments (SMA). Self-reported HRQoL was best in patients with HSP (mean EuroQoL Five Dimension Five Level (EQ-5D-5L) index value 0.67) and lowest in SMA patients (mean EQ-5D-5L index value 0.39). QALYs for patients with ALS were estimated to be 1.89 QALYs, 23.08 for patients with HSP and 14.97 for patients with SMA, respectively. Cost-utilities were estimated as follows: 138,960€/QALY for ALS, 525,033€/QALY for SMA, and 49,573€/QALY for HSP. The main predictors of the high cost of illness and low HRQoL were disease progression and loss of individual autonomy. Conclusion: As loss of individual autonomy was the main cost predictor, therapeutic and supportive measures to maintain this autonomy may contribute to reducing high personal burden and also long-term costs, e.g., care dependency and absenteeism from work. |
URI: | https://opendata.uni-halle.de//handle/1981185920/117124 http://dx.doi.org/10.25673/115168 |
Open-Access: | ![]() |
Nutzungslizenz: | ![]() |
Journal Titel: | Journal of neurology |
Verlag: | Steinkopff |
Verlagsort: | [Darmstadt] |
Band: | 270 |
Heft: | 10 |
Originalveröffentlichung: | 10.1007/s00415-023-11811-1 |
Seitenanfang: | 4922 |
Seitenende: | 4938 |
Enthalten in den Sammlungen: | Open Access Publikationen der MLU |
Dateien zu dieser Ressource:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
s00415-023-11811-1.pdf | 2.38 MB | Adobe PDF | ![]() Öffnen/Anzeigen |